Partially Hydrogenated Oils vs Acesulfame Potassium: which is worse?

What is Partially Hydrogenated Oils?

Partially hydrogenated oils (PHOs) are vegetable oils that have been treated with hydrogen gas in the presence of a catalyst to make them semi-solid at room temperature. This process creates artificial trans fatty acids (trans fats) as a byproduct. They were developed in the early 20th century as a cheaper, longer-lasting alternative to lard and butter.

What is Acesulfame Potassium?

Acesulfame potassium (Ace-K) is a calorie-free synthetic sweetener approximately 200 times sweeter than sucrose. It contains a potassium atom bonded to an oxathiazinone dioxide ring structure. It is heat-stable and non-metabolized, passing through the body unchanged. Often blended with sucralose or aspartame to mask bitter aftertaste.

Documented risks

Partially Hydrogenated Oils: Artificial trans fats (from PHOs) have the most well-established cardiovascular harm of any food ingredient ever banned. Multiple large meta-analyses have confirmed that trans fat consumption increases LDL ('bad') cholesterol, decreases HDL ('good') cholesterol, increases inflammatory markers, and significantly raises cardiovascular disease risk. The Harvard Nurses' Health Study and other landmark prospective studies in the 1990s identified trans fat as uniquely harmful — worse than saturated fat in its cardiovascular effects. A 2006 NEJM meta-analysis by Mozaffarian et al. estimated that eliminating artificial trans fats from the US diet could prevent 72,000 to 228,000 heart attacks per year and 30,000 to 100,000 coronary heart disease deaths annually. The WHO estimates that industrially produced trans fats cause over 500,000 cardiovascular deaths per year globally. The FDA revoked PHOs' GRAS status in 2015 based on this evidence, with compliance by 2018. Denmark banned artificial trans fats in 2003, the first country to do so, and observed a dramatic reduction in cardiovascular mortality in subsequent years.

Acesulfame Potassium: The safety database for Ace-K is considered less comprehensive than that for other sweeteners. Critics have argued that the original FDA approval studies from the 1970s-1980s were insufficient in quality and length to definitively establish long-term safety. The Center for Science in the Public Interest (CSPI) has petitioned for additional testing. Two rat studies found statistically significant increases in lung tumors (in male rats) and mammary tumors at high doses. Regulatory agencies have argued these doses far exceeded typical human exposure and attributed the tumor findings to other factors. However, the question of whether Ace-K's approval studies meet modern standards has been raised by independent researchers. A 2021 study in Cell found that Ace-K and other non-nutritive sweeteners altered gut microbiome composition and affected glucose tolerance in some human participants. Ace-K specifically was associated with changes in gut bacteria that correlated with glycemic effects. Neurological concerns: some animal studies suggest Ace-K may affect brain neurotransmitter systems. A 2013 study in PLoS ONE found that Ace-K consumption in pregnant mice altered offspring postnatal taste preference and increased weight gain, suggesting potential transgenerational effects. These findings were at doses exceeding typical human intake. Endocrine disruption potential has been raised in some in vitro studies, but comprehensive human data are lacking.